Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Licensing Deals Still Backloaded In 2013, But Biotechs Could Gain Leverage

Executive Summary

An analysis of alliance deals in 2013 shows pharmas’ continued reliance on heavily structured deals, a strategy that has often frustrated biotechs looking to partner. But the appetite for new IPO listings may be giving them more options, provoking competitive deal terms from licensors.

Advertisement

Related Content

Biopharma M&A In An Era Of Elusive Growth, Capital Triage, and New Competitors
Pharmas Among Biggest Cash Hoarders, Moody’s Finds
In 2012, Buyer’s Market Made Alliances Rarer
No Longer Aiming To Partner At Proof-of-Concept, Flexion Raises $20M For Late-Stage Trials

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel